Page last updated: 2024-12-07

cinchonidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CinchonagenusA genus of rubiaceous South American trees that yields the toxic CINCHONA ALKALOIDS from their bark; QUININE; QUINIDINE; chinconine, cinchonidine and others are used to treat MALARIA and CARDIAC ARRHYTHMIAS.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]

Cross-References

ID SourceID
PubMed CID101744
CHEMBL ID533841
CHEBI ID3703
SCHEMBL ID159532
MeSH IDM0123356

Synonyms (110)

Synonym
(r)-[(4s,5s,7s)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-quinolin-4-ylmethanol
chebi:3703 ,
(8s,9r)-cinchonan-9-ol
smr001233254
MLS002153905
BRD-K17661460-001-03-2
BRD-K17661460-001-04-0
nsc-5364
(-)-cinchonidine
KBIO1_000501
DIVK1C_000501
SDCCGMLS-0066969.P001
cinchonan-9-ol, (8-alpha,9r)-
ai3-15317
(8alpha,9r)cinchonan-9-ol
(8-alpha,9r)-cinchonan-9-ol
cinchonan-9-ol, (8alpha,9r)-
cinchonan-9-ol, (8a alpha,9r)-
einecs 207-622-3
nsc 5364
SPECTRUM_001165
BPBIO1_000564
PRESTWICK_66
PRESTWICK3_000606
BSPBIO_003450
BSPBIO_000512
IDI1_000501
(8alpha,9r)-cinchonan-9-ol
485-71-2
cinchonidine
(8s,9r)-cinchonidine
(r)-4-quinolyl-[(2s,4s,5r)-5-vinylquinuclidin-2-yl]methanol
cinchonidine, 96%
KBIOGR_001805
KBIO2_006781
KBIO2_004213
KBIOSS_001645
KBIO2_001645
KBIO3_002670
SPBIO_000937
SPECTRUM4_001173
SPECTRUM3_001745
SPECTRUM2_000719
NINDS_000501
SPECTRUM1500839
SPECTRUM5_002073
NCGC00178057-02
NCGC00178057-01
HMS2092M14
TCMDC-123934 ,
cinchovatine-
CHEMBL533841
HMS501J03
|a-quinidine
HMS1921K14
(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol
(s)-[(2r,4r,5s)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol
HMS2096J14
pharmakon1600-01500839
nsc-757800
nsc757800
HMS2235F22
AKOS016008633
CCG-36455
CCG-37735
unii-1u622lra8z
1u622lra8z ,
cinchonidine [who-ip]
(r)-((2s,4s,5r)-5-ethenyl-1-azabicyclo(2.2.2)oct-2-yl)(quinolin-4-yl)methanol [who-ip]
quinine sulfate impurity b [ep impurity]
quinine sulfate impurity b [who-ip]
cinchonidine [mi]
quinine bisulfate heptahydrate impurity b [who-ip]
quinine hydrochloride impurity b [ep impurity]
cinchonidine [who-dd]
quinine bisulfate impurity b [who-ip]
SCHEMBL159532
KMPWYEUPVWOPIM-KODHJQJWSA-N
(-)cinchonidine
(-) cinchonidine
STR04708
(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](quinolin-4-yl)methanol
cinchonan-9-ol, (8a,9r)-
AB00052182_03
mfcd00006783
HY-N0173
(-)-cinchonidine, 99% (total base), may cont. up to 5% quinine
SR-05000001575-8
sr-05000001575
(1r)-quinolin-4-yl((2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
cinchonidine, purum, >=98.0% (dried material, nt)
SR-05000001575-6
SR-05000001575-7
SR-05000001575-1
Z1954806302
SBI-0051617.P002
(-)-cinchonidine, analytical standard
CS-0007887
F15420
cinchonidine,(s)
(r)-quinolin-4-yl((2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
Q412713
BRD-K39079086-001-05-0
BRD-K39079086-001-07-6
NCGC00262526-04
(r)-quinolin-4-yl((1s,2s,4s,5r)-5-vinylquinuclidin-2-yl)methanol
DTXSID60883396
485-71-2 (free base)
-quinidine
EN300-708682

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The nature of the salt associated to the active principle can give some advantages in the field of activity, bioavailability and toxicity."( Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives.
Loiseau, PM; Nguyen, DX, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cinchona alkaloidAn alkaloid based on a cinchonan skeleton.
(8xi)-cinchonan-9-olCinchonan or (8S)-cinchonan in which one of the hydrogens at position 9 is substituted by hydroxy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
cinchona alkaloids biosynthesis010

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency7.94330.044717.8581100.0000AID485294
TDP1 proteinHomo sapiens (human)Potency21.83690.000811.382244.6684AID686978; AID686979
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID660168Inhibition of beta-hematin formation after 16 hrs at pH 5.2 by microplate reader2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID1233554Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream forms2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID660171Antimalarial activity against chloroquine resistant Plasmodium falciparum Dd2 after 72 hrs by SYBP Green I dye staining2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID660169Inhibition of beta-hematin formation after 16 hrs at pH 5.6 by microplate reader2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID660170Antimalarial activity against chloroquine sensitive Plasmodium falciparum HB3 after 72 hrs by SYBP Green I dye staining2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID158877In vitro inhibition of parasite development of Plasmodium falciparum W2 in human erythrocytes2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Synthesis and evaluation of new antimalarial analogues of quinoline alkaloids derived from Cinchona ledgeriana Moens ex Trimen.
AID764202Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream form assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID764198Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID764197Selectivity index, ratio of IC50 for human WI38 cells to IC50 for erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D72013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID764200Antileishmanial activity against Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID764199Antiplasmodial activity against erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1233560Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Plasmodium falciparum 3D72015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID764203Cytotoxicity against human WI38 cells by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID158875In vitro antimalarial activity against Plasmodium falciparum W2 in human erythrocytes by [3H]hypoxanthine uptake2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Synthesis and evaluation of new antimalarial analogues of quinoline alkaloids derived from Cinchona ledgeriana Moens ex Trimen.
AID764201Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream form2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (6.82)18.7374
1990's5 (5.68)18.2507
2000's31 (35.23)29.6817
2010's42 (47.73)24.3611
2020's4 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (97.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]